Gene editing strategies and translation to clinics

Carnot Imagine has extensive expertise in developing gene editing strategies (CRISPR/Cas, base, prime and epigenome editing). In vitro (patient-derived cells, iPSCs, organoids) and in vivo models (zebrafish, mice) have been developed to provide reliable tools for gene therapy product evaluation and optimization. In addition, a GMP facility and a clinical investigation center, affiliated to Carnot Imagine and specialized in evaluation of gene therapy products, ensure the translation to clinics.